What is the difference between AOD-9604 and GHRP-6?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. GHRP-6: Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is GHRP-6 administered in research settings?

In research settings, GHRP-6 is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs GHRP-6

Peptide Comparison

AOD-9604 vs GHRP-6

Name: AOD-9604 vs GHRP-6 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

197 providers listed

Full AOD-9604 profile →

GHRP-6

Growth Hormone Releasing Peptide-6

PerformanceUnder clinical reviewResearch Only

Half-life: 15-60 minutes

39 providers listed

Full GHRP-6 profile →

Bottom line

AOD-9604 is carried by more providers on PeptideBase (197 vs 39); otherwise the two are closely matched on the measures we track.

Quick Verdict

AOD-9604

Half-life

30–60 minutes

GHRP-6

Half-life

15-60 minutes

Which One Should You Choose?

Your goal	Better option
Oral administration option	AOD-9604
Lower typical price per mg	GHRP-6
More provider options (197 vs 39)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

GHRP-6

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

15-60 minutes

FDA Status

nomination withdrawn

Under clinical review

Admin Routes

subcutaneous, oral

subcutaneous, intranasal

Availability

Research Only

Providers

197 listed

39 listed

FDA Update

—

Under clinical review

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

Hexapeptide GH secretagogue. No FDA approval. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Historical Phase 2 trials (Theratechnologies) but abandoned. Research chemical.

Research Evidence

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

GHRP-6

Review · 1 key study · dated evidence base — most recent 1997

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

GHRP-6

Review1997 · European Journal of Endocrinology

Growth hormone-releasing peptides

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About GHRP-6

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

Research Areas

GH release via GHS-R1a agonism — synergistic with GHRHpronounced appetite stimulation (ghrelin-mimetic effect)muscle recovery and GH pulse amplificationco-stimulation of cortisol and prolactin — less selective than ipamorelin

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

GHRP-6

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

IGF-1Fasting glucoseHbA1cCortisolInsulin

GHRP-6 produces stronger cortisol and prolactin stimulation than selective GH peptides. Research protocols measure IGF-1 for GH axis response and baseline cortisol. Glucose markers are standard given GH's effect on insulin sensitivity.

Used Together?

GHRP-6

Corticosteroids
Research notes that GHRP-6 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.

Price (per mg)

AOD-9604

$9.00/mg

$7.71 – $11.85 range

45 vendors

View price index →Find providers →

GHRP-6

$4.60/mg

$3.18 – $6.65 range

20 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

197 listed

Browse directory →

Providers offering

GHRP-6

39 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs GHRP-6 — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/aod-9604/ghrp-6

https://peptidebase.io/peptides/compare/aod-9604/ghrp-6 Methodology License Download JSON Download CSV